Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))

Elizabeth R. Plimack; Thomas Powles; Viktor Stus; Rustem Gafanov; Dmitry Nosov; Tom Waddell; Boris Alekseev; Frédéric Pouliot; Bohuslav Melichar; Denis Soulières; Delphine Borchiellini; Raymond S. McDermott; Ihor Vynnychenko; Yen Hwa Chang; Satoshi Tamada; Michael B. Atkins; Chenxiang Li; Rodolfo Perini; L. Rhoda Molife; Jens Bedke; Brian I. Rini

doi:10.1016/j.eururo.2023.08.010

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))

Elizabeth R. Plimack
, Thomas Powles
, Viktor Stus
, Rustem Gafanov
, Dmitry Nosov
, Tom Waddell
, Boris Alekseev
, Frédéric Pouliot
, Bohuslav Melichar
, Denis Soulières
, Delphine Borchiellini
, Raymond S. McDermott
, Ihor Vynnychenko
, Yen Hwa Chang
, Satoshi Tamada
, Michael B. Atkins
, Chenxiang Li
, Rodolfo Perini
, L. Rhoda Molife
, Jens Bedke

Brian I. Rini

Royal Free London NHS Foundation Trust
Queen Mary University of London
Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
Russian Ministry of Health
Central Clinical Hospital With Outpatient Clinic
The Christie NHS Foundation Trust
Université Laval
Palacký University Olomouc
Centre Hospitalier de l’Université de Montréal Research Center
Université Côte d'Azur
University College Dublin
Sumy State University
Veterans General Hospital-Taipei
Bell Land General Hospital
Georgetown University
Merck & Co.
MSD UK
University of Tübingen
Vanderbilt University

Research output: Contribution to journal › Comment/debate

5 Scopus citations

Abstract

The authors regret re report that upon review of the publication, we have become aware of a typo in Table A. where “112” patients should read “12”.[Formula presented] The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	e123-e124
Journal	European Urology
Volume	84
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2023.08.010
State	Published - Nov 2023

Access to Document

10.1016/j.eururo.2023.08.010

Fingerprint

Dive into the research topics of 'Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))'. Together they form a unique fingerprint.

Cite this

Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., Alekseev, B., Pouliot, F., Melichar, B., Soulières, D., Borchiellini, D., McDermott, R. S., Vynnychenko, I., Chang, Y. H., Tamada, S., Atkins, M. B., Li, C., Perini, R., Rhoda Molife, L., ... Rini, B. I. (2023). Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006)). European Urology, 84(5), e123-e124. https://doi.org/10.1016/j.eururo.2023.08.010

Plimack, Elizabeth R. ; Powles, Thomas ; Stus, Viktor et al. / Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006)). In: European Urology. 2023 ; Vol. 84, No. 5. pp. e123-e124.

@article{218389d5a9164e93958ee33c242ff657,

title = "Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))",

abstract = "The authors regret re report that upon review of the publication, we have become aware of a typo in Table A. where “112” patients should read “12”.[Formula presented] The authors would like to apologise for any inconvenience caused.",

author = "Plimack, \{Elizabeth R.\} and Thomas Powles and Viktor Stus and Rustem Gafanov and Dmitry Nosov and Tom Waddell and Boris Alekseev and Fr{\'e}d{\'e}ric Pouliot and Bohuslav Melichar and Denis Souli{\`e}res and Delphine Borchiellini and McDermott, \{Raymond S.\} and Ihor Vynnychenko and Chang, \{Yen Hwa\} and Satoshi Tamada and Atkins, \{Michael B.\} and Chenxiang Li and Rodolfo Perini and \{Rhoda Molife\}, L. and Jens Bedke and Rini, \{Brian I.\}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = nov,

doi = "10.1016/j.eururo.2023.08.010",

language = "English",

volume = "84",

pages = "e123--e124",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "5",

}

Plimack, ER, Powles, T, Stus, V, Gafanov, R, Nosov, D, Waddell, T, Alekseev, B, Pouliot, F, Melichar, B, Soulières, D, Borchiellini, D, McDermott, RS, Vynnychenko, I, Chang, YH, Tamada, S, Atkins, MB, Li, C, Perini, R, Rhoda Molife, L, Bedke, J & Rini, BI 2023, 'Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))', European Urology, vol. 84, no. 5, pp. e123-e124. https://doi.org/10.1016/j.eururo.2023.08.010

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006)). / Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor et al.
In: European Urology, Vol. 84, No. 5, 11.2023, p. e123-e124.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma

T2 - 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))

AU - Plimack, Elizabeth R.

AU - Powles, Thomas

AU - Stus, Viktor

AU - Gafanov, Rustem

AU - Nosov, Dmitry

AU - Waddell, Tom

AU - Alekseev, Boris

AU - Pouliot, Frédéric

AU - Melichar, Bohuslav

AU - Soulières, Denis

AU - Borchiellini, Delphine

AU - McDermott, Raymond S.

AU - Vynnychenko, Ihor

AU - Chang, Yen Hwa

AU - Tamada, Satoshi

AU - Atkins, Michael B.

AU - Li, Chenxiang

AU - Perini, Rodolfo

AU - Rhoda Molife, L.

AU - Bedke, Jens

AU - Rini, Brian I.

PY - 2023/11

Y1 - 2023/11

N2 - The authors regret re report that upon review of the publication, we have become aware of a typo in Table A. where “112” patients should read “12”.[Formula presented] The authors would like to apologise for any inconvenience caused.

AB - The authors regret re report that upon review of the publication, we have become aware of a typo in Table A. where “112” patients should read “12”.[Formula presented] The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85169922522

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001092250500001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.eururo.2023.08.010

DO - 10.1016/j.eururo.2023.08.010

M3 - Comment/debate

C2 - 37666734

SN - 0302-2838

VL - 84

SP - e123-e124

JO - European Urology

JF - European Urology

IS - 5

ER -

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T et al. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006)). European Urology. 2023 Nov;84(5):e123-e124. doi: 10.1016/j.eururo.2023.08.010

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] (European Urology (2023) 84(5) (449–454), (S0302283823029019), (10.1016/j.eururo.2023.06.006))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this